Stock Financial Ratios, Dividends, Split History

ESL / Esterline Technologies Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,136.46
Enterprise Value ($M)2,751.93
Book Value ($M)1,792.95
Book Value / Share60.93
Price / Book1.19
NCAV ($M)1,320.87
NCAV / Share44.88
Price / NCAV1.61
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 29,767,000
Weighted Average Number Of Diluted Shares Outstanding 30,003,000
Common Stock Shares Outstanding 29,981,546
Common Shares Outstanding 29,984,434
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.04
Return on Equity (ROE)0.07
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio3.29
Income Statement (mra) ($M)
Sales Revenue Net2,002,195,000.00
Disposal Group Including Discontinued Operation Revenue4,964,000.00
Net Income118.89
Earnings Per Share Basic3.94
Earnings Per Share Diluted3.91
Cash Flow Statement (mra) ($M)
Cash From Operations193.46
Cash from Investing-57.44
Cash from Financing-57.44
Identifiers and Descriptors
Central Index Key (CIK)33619
Related CUSIPS
297425950 029742510 297425900

Split History

Stock splits are used by Esterline Technologies Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

RPM International: Limited Upside, But Enjoy The Dividends

2018-06-11 seekingalpha
RPM International sells coatings, sealants and building materials through three core segments: Industrial, Consumer and Specialty. (7-0)

Esterline Technologies: Limited Upside

2018-06-11 seekingalpha
Esterline Technologies is a strong, stable company with about $2 billion in annual revenue, with around $150 million in free cash flow per annum. (3-0)

Esterline Technologies Corporation 2018 Q2 - Results - Earnings Call Slides

2018-05-04 seekingalpha
The following slide deck was published by Esterline Technologies Corporation in conjunction with their 2018 Q2 earnings call. (1-0)

Esterline Technologies (ESL) Q2 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Good afternoon, and welcome, ladies and gentlemen, to the Esterline Technologies Fiscal Second Quarter 2018 Earnings Conference Call. At this time, I'd like to inform you that this conference is being recorded. Following our prepared remarks, we will open the conference for questions-and-answers. A replay of today's call will be available for one week by calling this toll free number, 855-859-2056. (55-0)

Aerospace Stocks Q1 Earnings Due on May 3: HII, OA & More

2018-05-02 zacks
Over the last week, Wall Street saw first-quarter 2018 earnings releases from several defense biggies like Lockheed Martin, Boeing, Northrop Grumman and General Dynamics. L-3 Technologies (LLL - Free Report) kick-started this week by reporting better-than-expected result for the first quarter. Today, Spirit AeroSystems (SPR - Free Report) is set to release Q1 numbers. (21-0)

CUSIP: 297425100